160 related articles for article (PubMed ID: 34890212)
1. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
Norsworthy KJ; Gao X; Ko CW; Pulte ED; Zhou J; Gong Y; Shen YL; Vallejo J; Gwise TE; Sridhara R; Deisseroth AB; Farrell AT; de Claro RA; Blumenthal GM; Pazdur R
J Clin Oncol; 2022 Mar; 40(8):847-854. PubMed ID: 34890212
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
3. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
4. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
5. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia.
Huang J; Gui C; Zhang L; Che F; Wang C
Cell Physiol Biochem; 2018; 49(4):1589-1599. PubMed ID: 30223267
[TBL] [Abstract][Full Text] [Related]
8. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
[TBL] [Abstract][Full Text] [Related]
10. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
Walter RB; Kantarjian HM; Huang X; Pierce SA; Sun Z; Gundacker HM; Ravandi F; Faderl SH; Tallman MS; Appelbaum FR; Estey EH
J Clin Oncol; 2010 Apr; 28(10):1766-71. PubMed ID: 20159819
[TBL] [Abstract][Full Text] [Related]
11. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
[No Abstract] [Full Text] [Related]
12. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
14. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
15. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
16. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
17. [Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):185-191. PubMed ID: 28395440
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis.
Guo Y; Deng L; Qiao Y; Liu B
Hematology; 2022 Dec; 27(1):53-64. PubMed ID: 34957930
[No Abstract] [Full Text] [Related]
19. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.
Mao C; Fu XH; Yuan JQ; Yang ZY; Huang YF; Ye QL; Wu XY; Hu XF; Zhai ZM; Tang JL
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010248. PubMed ID: 26544114
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry.
Martínez-Cuadrón D; Megías-Vericat JE; Gil C; Bernal T; Tormo M; Martínez-Sánchez P; Rodríguez-Medina C; Serrano J; Herrera P; Simón JAP; Sayas MJ; Bergua J; Lavilla-Rubira E; Amigo ML; Benavente C; Lorenzo JLL; Pérez-Encinas MM; Vidriales MB; Colorado M; De Rueda B; García-Boyero R; Marini S; García-Suárez J; López-Pavía M; Gómez-Roncero MI; Noriega V; López A; Labrador J; Cabello A; Sossa C; Algarra L; Stevenazzi M; Solana-Altabella A; Boluda B; Montesinos P
Haematologica; 2024 Jan; 109(1):115-128. PubMed ID: 37199127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
